These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31805210)

  • 21. Would apixaban be a good option for extended anticoagulation in venous thromboembolism?
    Wu MA; Cernuschi G
    Intern Emerg Med; 2014 Feb; 9(1):99-100. PubMed ID: 23857037
    [No Abstract]   [Full Text] [Related]  

  • 22. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
    Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of Hemostatic Outcomes in Patients Receiving Fixed-Dose vs. Weight-Based 4-Factor Prothrombin Complex Concentrate.
    Kim C; Cottingham L; Eberwein K; Komyathy K; Ratliff PD
    J Emerg Med; 2020 Jul; 59(1):25-32. PubMed ID: 32536491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study.
    Wilsey HA; Bailey AM; Schadler A; Davis GA; Nestor M; Pandya K
    J Intensive Care Med; 2021 May; 36(5):597-603. PubMed ID: 32242482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban.
    Sheikh-Taha M
    Intern Emerg Med; 2020 Sep; 15(6):1123-1124. PubMed ID: 31664661
    [No Abstract]   [Full Text] [Related]  

  • 28. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
    Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
    Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
    Phillips A; Bradley C; Cash J; Sangiovanni R; Wingerson C
    Am J Health Syst Pharm; 2024 May; 81(11):e274-e282. PubMed ID: 38430127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding.
    Smythe MA; Koerber JM; Hoffman JL; Mertz S; Fritsch K; Chehab F; Baalbaki N; Krishnan A
    Thromb Res; 2021 Oct; 206():142-144. PubMed ID: 34481221
    [No Abstract]   [Full Text] [Related]  

  • 32. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
    Nagalla S; Thomson L; Oppong Y; Bachman B; Chervoneva I; Kraft WK
    Clin Transl Sci; 2016 Jun; 9(3):176-80. PubMed ID: 27170068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Xa activity in apixaban overdose: a case report.
    Barton J; Wong A; Graudins A
    Clin Toxicol (Phila); 2016 Nov; 54(9):871-873. PubMed ID: 27436437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.